炎症在癌症的发展过程中起着重要作用。近年来,评估炎症生物标志物预测生存能力的研究数量有所增加。本研究旨在全面评估炎性生物标志物在喉癌患者接受确定性放疗中的预测作用。回顾性检查了在我们中心接受喉癌明确放疗的101例患者。患者放疗前取血样获取C反应蛋白(CRP)等生物标志物,中性粒细胞-淋巴细胞比率(NLR),血小板-淋巴细胞比率(PLR),单核细胞-淋巴细胞比率(MLR),全身免疫炎症指数(SII),泛免疫炎症值(PIV),血嗜酸性粒细胞炎症指数(HEI),白蛋白,和乳酸脱氢酶(LDH)。该研究检查了无进展生存期(PFS)参数的预测价值,无局部复发生存率(LRFS),使用单变量和多变量Cox回归分析和总生存期(OS)。在单变量分析中,预测PFS的生物标志物是SII,PIV,CRP,和东部肿瘤协作组绩效状态(ECOGPS)。根据多变量分析,只有CRP被发现是PFS的显著预测因子.在单变量分析中,发现以下生物标志物可以预测OS:NLR,PLR,MLR,SII,PIV,CRP,HEI,舞台,和ECOGPS。在多变量分析中,发现NLR和ECOGPS是OS的预测因子。在MLR中发现了显著差异,PIV,和基于淋巴转移的CRP值。当前的研究是第一个全面检查喉癌与几种炎症生物标志物之间关系的研究。这些生物标志物中的许多已被证明可以预测正在接受明确放射治疗的喉癌患者的PFS和OS。已显示,除PFS和OS外,PIV和CRP还可以预测淋巴转移的存在。
Inflammation plays an important role in the process of cancer development. The number of studies evaluating the ability of inflammatory biomarkers to predict survival has increased in recent years. This study aimed to comprehensively evaluate the predictive role of inflammatory biomarkers in patients with larynx cancer undergoing definitive radiotherapy. A total of 101 patients who underwent definitive radiotherapy for larynx cancer at our center were retrospectively examined. Blood samples were taken from the patients before radiotherapy to obtain biomarkers such as C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), pan-immune inflammatory value (PIV), hemo-eosinophil inflammation index (HEI), albumin, and Lactate dehydrogenase (LDH). The study examined the predictive value of parameters for progression-free survival (PFS), local recurrence-free survival (LRFS), and overall survival (OS) using both univariate and multivariate Cox regression analysis. In the univariate analysis, the biomarkers that predicted PFS were SII, PIV, CRP, and Eastern Cooperative Oncology Group Performance Status (ECOG PS). According to the multivariate analysis, only CRP was found to be a significant predictor of PFS. In the univariate analysis, the following biomarkers were found to predict OS: NLR, PLR, MLR, SII, PIV, CRP, HEI, stage, and ECOG PS. In the multivariate analysis, NLR and ECOG PS were found to be predictors of OS. A significant difference was found in MLR, PIV, and CRP values based on the presence of lymphatic metastasis. The current study is the first to comprehensively examine the relationship between larynx cancer and several inflammatory biomarkers. Many of these biomarkers have been shown to predict both PFS and OS in patients with larynx cancer undergoing definitive radiotherapy. It has been shown that PIV and CRP may predict the presence of lymphatic metastases in addition to PFS and OS.